Reimagining Medicine
Company overview
Innovation: Pipeline overview
Cardiovascular
Ophthalmology
BeovuⓇ - VEGF Inhibitor
NCT04278417 (CRTH258D2301)
Indication
Diabetic retinopathy
Phase 3
Change from Baseline in BCVA
Phase
Patients
706
Primary
Outcome
Measures
Arms
Financial review
Immunology
Intervention
Target
Patients
Arm1: RTH258 (brolucizumab) 6 mg/50uL
Arm2: Panretinal photocoagulation laser initial treatment followed with
additional PRP treatment as needed
Patients with proliferative diabetic retinopathy
Readout
Milestone(s)
2024
Publication
TBD
2023 priorities
Innovation: Clinical trials
Neuroscience
Global Health
Appendix
Abbreviations
Oncology
Other
Biosimilars
97 Investor Relations | Q4 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation